BMAC – Biopharmaceutical Manufacturer's Advisory Council

Seniors can self-administer the screening of dementia or MCI using artificial intelligence

Share
BMAC - Biopharmaceutical Manufacturer's Advisory Council

Seniors in Singapore can use an artificial intelligence-based technology to self-administer the screening of dementia or mild cognitive impairment.

Based on their test results, general practitioners can develop a personalised care plan or provide timely medical intervention.

The AI-based technology is being used for the first time in Asia and Singapore to detect dementia in seniors. Developed by British medical technology company Cognetivity, this comprehensive cognitive assessment app known as ‘CognICA’ can accurately evaluate a person’s mental and cognitive function.

Lions Befrienders signed a Memorandum of Understanding (MOU) with five BMAC companies to bring this AI-based technology from England into Singapore.

These five BMAC companies will send at least 50 volunteers to provide one-to-one coaching to seniors on self-administering using the technology. Once the app is launched, the cognitive ability of a senior is detected through a 5minute game that uses natural images of animals. The speed and accuracy of a senior doing the test act as a digital biomarker for an assessment of their cognitive function. 

通过人工智能应用 年长者可自测是否失智

本地年长者日后可使用人工智能应用,自行检测是否患 上失智症或轻度认知障碍。全科医生可根据检测结果,为年 长者量身定制个人护理计划,或在必要时进行干预治疗。

这是亚洲和新加坡首次采用这类人工智能技术,为年长 者检测失智症。这款名为“CognICA”的综合认知能力评 估应用,由英国医疗技术公司Cognetivity开发,可准确测量 一个人的精神认知功能。   

社会服务机构狮子乐龄之友协会(Lions Befrienders) 日前与医药制造商咨询委员会旗下的五家制药公司签署谅解 备忘录,把这项检测技术从英国引进新加坡。  

这五家制药公司会派出至少50名义工,一对一指导年 长者如何自行检测。年长者开启应用后,只须在五分钟的游 戏中辨认快速闪过的动物图像,应用就可根据年长者辨认的 速度和准确度,有效评估他们的认知功能。

BMAC - Biopharmaceutical Manufacturer's Advisory Council

Related News